Abstract
Objectives To identify echocardiographic signatures featuring left ventricular longitudinal strain (LS) associated with genetic risk for cardiac amyloidosis (CA) due to the TTR Val142Ile (V142I) variant in African American (AA) and Hispanic/Latinx (H/L) individuals.
Background Hereditary transthyretin amyloidosis (hATTR) can cause CA in ∼60-70% of older V142I carriers, but amyloid deposition progresses over many years. Disease-modifying therapy for CA is now available and early initiation is a priority for improving outcomes. Genomic screening programs and familial cascade genetic testing uncover pre-symptomatic V142I carriers, yet no guidelines exist for early CA detection.
Methods Exome sequencing data linked to electronic health records (EHRs) of BioMe biobank participants were queried for AA or H/L TTR- and TTR+ (V142I) subjects without hATTR diagnoses and with prior echocardiograms suitable for retrospective LS analysis. Systemic “red flag” features of ATTR were extracted from EHRs of TTR+ subjects. Speckle tracking echocardiography was retrospectively applied to determine global (GLS) and segmental LS. Relative apical sparing (RAS) was calculated.
Results 57 TTR+ and 46 TTR-age- and ancestry-matched subjects were included. GLS declined with age in females but not males, and was abnormal (<16%) in 18 (31.6%) TTR+ and 7 (15.2%) TTR-subjects (p = 0.066). Apical sparing was observed in 13 (22.8%) TTR+ and 11 (23.9%) TTR-subjects (p = 1.0). After adjusting for relevant demographic and echocardiographic covariates, neither GLS nor RAS was associated with TTR+ V142I status. Red flag features were not associated with GLS or RAS in TTR+ subjects.
Conclusions Neither GLS nor RAS were significantly different between TTR+ and TTR-subjects. Since >50% of TTR+ subjects were ≥ 60 years old, penetrance of CA by echocardiography among unselected V142I carriers may be lower than previously estimated. These findings indicate that surveillance for CA in individuals at increased genetic risk due to V142I should not rely solely on echocardiography, even with LS.
Competing Interest Statement
A.R.K has served on the Advisory Board for Alynlam Pharmaceuticals. S.S.M has served on the Speakers Bureau for Abbott Laboratories and received an Honorarium from Heart Failure Society of America. N.S.A-H was previously employed by Regeneron Pharmaceuticals and has received a speaker honorarium from Genentech. E.E.K has received speaker honoraria from Illumina and Regeneron Pharmaceuticals.
Funding Statement
A.R.K received funding from NIH NHLBI (K23 HL140083).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Mount Sinai Institutional Review Board (GCO # 19-01925 ISMMS).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: A.R.K received funding from NIH NHLBI (K23 HL140083).
Financial Disclosures: A.R.K has served on the Advisory Board for Alynlam Pharmaceuticals. S.S.M has served on the Speaker’s Bureau for Abbott Laboratories and received an Honorarium from Heart Failure Society of America. N.S.A-H was previously employed by Regeneron Pharmaceuticals and has received a speaker honorarium from Genentech. E.E.K has received speaker honoraria from Illumina and Regeneron Pharmaceuticals.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
